THERAPY DOSSIER · th-20eb55533d9f

Carvedilol

Drug · Non-selective beta-adrenoceptor antagonist with additional alpha-1 adrenoceptor antagonism; both ANTAGONIST, direct interaction, disease efficacy true. ATC C07AG02. Salt form CHEMBL1201167 (carvedilol phosphate, approved 2006) maps to the same parent.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Non-selective beta-adrenoceptor antagonist with additional alpha-1 adrenoceptor antagonism; both ANTAGONIST, direct interaction, disease efficacy true. ATC C07AG02. Salt form CHEMBL1201167 (carvedilol phosphate, approved 2006) maps to the same parent.
Target: CHEMBL2094118; CHEMBL2094251
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 1995
Development stage: Not recorded
ChEMBL record: CHEMBL723 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Carvedilol; Coreg; Dilatrend; Eucardic; Kredex; BM-14190; SKF-105517
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02907749 ↗PHASE4completed

Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease

Cirrhosis · Portal Hypertension

Enrolment: 96 · Results not recorded

NCT07397481 ↗PHASE4completed

Dose Prediction for Antihypertensive Medications in Cirrhotic Patients Using Simcyp Program

Liver Cirrhosis · Arterial Hypertension

Enrolment: 40 · Results not recorded

NCT00323037 ↗PHASE3completed

Coreg CR vs Coreg IR on Left Ventricular End Systolic Volume Index in Stable Chronic Heart Failure

Congestive Heart Failure

Enrolment: 318 · Results not recorded

NCT00272805 ↗PHASE3completed

COREG CR vs COREG IR on Compliance and Quality of Life in Heart Failure With LV Systolic Dysfunction

Chronic Heart Failure

Enrolment: 400 · Results not recorded

NCT04218968 ↗PHASE2active not recruiting

Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Parkinson's Disease

REM Sleep Behavior Disorder · Pre-motor Parkinson Disease · Symptomatic Parkinson Disease

Enrolment: 15 · Results not recorded

NCT01793870 ↗PHASE1completed

A Four Way Crossover Study in Healthy Volunteers to Evaluate a Stable Isotope Approach for PK Studies

Metabolic, Cardiovascular

Enrolment: 17 · Results not recorded

NCT01819870 ↗PHASE1unknown

Phase I Study Comparing Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects

Essential Hypertension · Chronic Stable Angina · Congestive Heart Failure

Enrolment: 48 · Results not recorded

NCT00249067 ↗Phase not recordedterminated

Retrospective Evaluation of Carvedilol Versus Captopril and Digoxin/Lasix Therapy in Congestive Heart Failure

Heart Failure · Heart Murmurs

Enrolment: 50 · Results not recorded

NCT06015373 ↗NAcompleted

The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension

Clinically Significant Portal Hypertension

Enrolment: 34 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25424914 ↗2015Reported benefit

Carvedilol promotes neurological function, reduces bone loss and attenuates cell damage after acute spinal cord injury in rats.

RatSpinal cord injuryUnspecifiedSprague-DawleyFemaleOral gavage10 mg/kgAfter spinal cord injury

Model: Acute spinal cord injury

Carvedilol significantly improved locomotor activity, increased tibial bone mineral density through altered RANKL and osteoprotegerin expression, reduced neural damage and astrocyte activation, lowered inflammatory cytokines and oxidative stress, and decreased Fas, Fas ligand, cleaved caspase 3 and…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…